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Accepted 6 January 2016Myasthenia gravis (MG) patients with antibodies against the muscle speciﬁc tyrosine kinase (MuSK+) have
predominantly involvement of cranio-bulbar muscles and do not display thymus pathology, as do acetylcholine
receptor antibody seropositive (AChR+) MG patients. In search of novel biomarkers for MuSK+ MG, we
evaluated circulating serum microRNAs. Four analyzed microRNAs were speciﬁcally elevated in MuSK+ MG
patient serum samples: let-7a-5p, let-7f-5p, miR-151a-3p and miR-423-5p. The circulating microRNA proﬁle in
MuSK+ MG differs from the proﬁle previously observed in the serum of AChR+ MG, thus indicating the
etiological difference between these two entities. We propose that the identiﬁed microRNAs could serve as
potential serum biomarkers for MuSK+ MG.
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Myasthenia gravis (MG) is a chronic autoimmune disorder, caused
by an antibody-mediated attack against proteins of the neuromuscular
junction (Berrih-Aknin, 2014). In a subtype of MG, antibodies (abs) tar-
get the postsynapticmuscle speciﬁc tyrosine kinase (MuSK+).MuSK+
MG, that represents approximately 5–7% of the MG spectrum, appears
to be more common in Mediterranean countries and is predominantly
characterized by involvement of cranio-bulbar muscles and an in-
creased rate of muscle wasting (Evoli et al., 2003). MuSK abs differenti-
ate themselves in that they are mainly of the IgG4 subtype compared to
the more common form of MG with predominantly IgG1 subtype abs
against the acetylcholine receptor (AChR+). TheMuSK IgG4 abs inhibit
agrin-dependent MuSK activation by interfering with Lrp4-MuSK bind-
ing, and this is considered one of the key effector mechanisms of the
MuSK abs (Huijbers et al., 2013; Koneczny et al., 2013). The MuSK
IgG4 abs vary from other IgG antibodies in various functional aspects;
for example, IgG4 abs do not activate the complement system. Still,nce, Clinical Neurophysiology,
ppsala, Sweden.
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. This is an open access article underprominent B-cell pathology, that has been described in AChR+ MG,
was recently reported in MuSK+MG (Guptill et al., 2015).
MuSK abs are very speciﬁc and their detection in patients with ob-
jective signs of skeletal muscle fatigue and disturbed neuromuscular
transmission conﬁrms MG diagnosis. Furthermore, serum concentra-
tion of MuSK abs decreases upon immunosuppression and correlates
with disease severity (Bartoccioni et al., 2006). Nevertheless, the
MuSK ab titer does not necessarily predict the course of the disease
and thus more reliable biomarkers are needed for individual treatment
and clinical trials (Kaminski et al., 2012; Meriggioli and Sanders, 2012).
Mammalian microRNAs (miRNAs) are important small non-coding
regulatory RNAs that impede gene expression by blocking translation
of their target messenger RNAs (mRNAs) (Krol et al., 2010). Quantita-
tive detection of cellular miRNAs can be used to describe disease status,
as abnormal presence of certain miRNAs correlates with the pathogen-
esis of diseases such as cancer and diabetes (Esteller, 2011; Kasinski and
Slack, 2011). In addition to their intracellular accumulation,miRNAs can
also be released from the cells into the extracellular space. The released
miRNAs enter the circulation packed into the exosomes, where the
miRNAs are protected from degradation (Zhang et al., 2015). The de-
tection of circulating miRNAs in patient bioﬂuids has been considered
a novel approach to detect progression of cardiovascular diseases and
malignant growth (Creemers et al., 2012; Etheridge et al., 2011)
as well as monitoring the disease state in multiple sclerosis (MS)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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miR-151-5p and miR-21-5p as disease-speciﬁc miRNAs with dif-
ferent accumulation patterns in immunosuppressed and non-
immunosuppressed patient sera (Punga et al., 2014, 2015). Since
MuSK+ MG clinical phenotype is different from AChR+ MG, it
would be important to analyze the possible involvement of circulat-
ing miRNAs in this MG entity.
Thus, the aim of the present study was to identify serum circulating
miRNAs speciﬁc for MuSK+ MG patients.
2. Material and methods
2.1. Subjects
In this study we included 25 patients with MuSK+MG, in different
stages of their disease, who were regularly followed at the Neurology
Clinic of the Catholic University Hospital, Rome, Italy. At time of diagno-
sis, all patients had muscle weakness and fatigability, together with ev-
idence of impaired neuromuscular transmission during low-frequency
repetitive nerve stimulation and/or single-ﬁber EMG, and positive
serum MuSK ab titers (N0.05 nM/l) in a standard radioimmuno-
precipitation assay. Three patients never received any immunosuppres-
sive therapy, 9 patients were treated with prednisone and 13 patients
were treated with prednisone and other immunosuppressants; two of
these patients received rituximab. At time for blood sampling six pa-
tients did not have any ongoing immunosuppression (Table 1). Three
patients had undergone thymectomy and in all, histologic examination
revealed a thymus that was histopathologically normal for their age.
Serum sampleswere obtained fromMGpatients and from age and gen-
der matched healthy controls after informed consent. These studies
were approved by the local Ethics Committees [Uppsala-Sweden
(Dnr. 2010/446) and Rome, Italy (authorization number ID P/529/
CE/2011))]. Disease severity was classiﬁed according to the
Myasthenia Gravis Foundation of America (MGFA) system (JaretzkiTable 1
Clinical data on the 25MuSK antibody seropositive patients assayed. Disease dur (duration) is st
of America; IS, immunosuppressive; pred; prednisone; AZA, azathioprine; CyA, cyclosporine
remission. **Treatments with rituximabwere given. N-m failure; examination of neuromuscula
SFEMG, single ﬁber electromyography.−, normal; +, abnormal neuromuscular transmission;
Pat # Age/sex Disease dur Max MGFA
grade
IS therapy during
disease course
Discovery set (N = 10)
1 59F 46 3b None
2 61F 9 3b Pred, AZA
3 39M 8 2b Pred
4 47F 15 3b Pred, CyA
5 35F 22 5 Pred, AZA
Validation set (N = 40)
11 81F 10 2b None
12 59F 1 5 Pred, AZA
13 60M 2 2b Pred
14 64F 16 5 Pred, AZA
15 62F 2 2b None
16 31M 3 3b Pred
17 24F 8 3b Pred, AZA
18 48M 18 3b Pred
19 28M 2 3b Pred
20 43M 5 3b Pred, AZA, MMF**
21 61M 6 3b Pred, AZA, MMF
22 36F 16 3b Pred
23 38F 4 4b Pred, AZA
24 45F 9 5 Pred
25 42F 4 5 Pred, AZA
26 35M 10 3b Pred
27 41F 1 4b Pred, AZA, CyA, MMF
28 34F 5 5 Pred, AZA, CyA**
29 27F 15 5 Pred, AZA
30 21F 1 3b Predet al., 2000); clinical status at the time of the study was graded ac-
cording to a semi-continuous disease severity score (DSS) (Niks
et al., 2008).
The discovery set (N = 10) included ﬁve MuSK+ MG patients, out
of whom three were on immunosuppressive therapy (see Table 1).
The discovery set also included ﬁve age- and gender-matched healthy
Italian controls (HCs).
The validation set (N=40) consisted of 20MuSK+MGpatients and
20 age-and gender-matched healthy controls. Demographics of the dis-
covery and validation sets are shown in Table 1. All patients and healthy
controls were of Italian ethnicity.
2.2. Serum circulating miRNA isolation
Blood samples were collected in tubes without any additives, stored
at room temperature for at least 20 min, and then centrifuged at
4000 rpm at 20 °C for 5 min. Total RNA was isolated from 200 μl
serum by using a miRCURY™ RNA Isolation Kit-Bioﬂuids (Exiqon
#300112), according to the manufacturer's instructions. Two microli-
ters of isolated RNA sample was used for cDNA synthesis in 10 μl reac-
tion mix using the Universal cDNA Synthesis Kit II (Exiqon #203301).
2.3. Serum circulating miRNA expression analysis
2.3.1. miRNA analysis using microRNA PCR panel
Initial miRNA detection experiments were performed on Serum/
Plasma Focus microRNA PCR Panel (V4.M) using ExiLENT SYBR®
Greenmaster mix (Exiqon #203420) as recommended by themanufac-
turer. This panel covers the detection primers for 179 human miRNAs
and was used for proﬁling the discovery set of ﬁve patients and ﬁve
age- and gender-matched HCs. The qRT-PCR data from Serum/Plasma
Focus microRNA PCR Panels were examined with GenEx software
(Exiqon) according to the recommendations from Exiqon. In this pro-
cess the inter-plate calibration, approved quality controls (RNA-spike-ated in years fromMGdiagnosis. M,male; F, female;MGFA;Myasthenia Gravis Foundation
; MMF, mycophenolate; RTX; rituximab; *pharmacological remission; #complete stable
r transmission failure with neurophysiological methods. RNS, repetitive nerve stimulation;
n.p., not performed. HC, healthy control. Current MuSK antibody (ab) titer is stated.
MuSK ab
titer (nM)
MG grade IS now N-m failure
RNS/ SFEMG
HC
Age/sex
4.7 3 No +/+ 59F
3.5 3 Yes n.p/+ 62F
0.5 1# No n.p/+ 39M
6 2 Yes −/+ 50F
12.3 3 Yes +/+ 36F
5.3 2 No −/+ 82F
3.98 2 Yes +/+ 59F
6.4 1* Yes −/+ 60M
5.48 3 Yes −/+ 64F
1.5 2 No −/+ 62F
7.19 2 Yes n.p./+ 31M
2.8 2 Yes −/+ 20F
3 2 No −/+ 48M
0.5 2 Yes +/n.p 30M
8.08 3 Yes +/+ 41M
0.91 2 Yes +/n.p. 61M
5.9 2 Yes +/+ 36F
0.9 2 Yes +/+ 38F
0 1* Yes +/n.p. 47F
39 3 Yes −/+ 43F
0.8 1# No −/+ 34M
7.33 3 Yes −/+ 38F
5.95 3 Yes +/n.p. 33F
0 1* Yes +/+ 28F
0.80 2 Yes −/+ 26F
Table 2
Differentially expressed miRNAs in the discovery set. Selection of miRNAs of interest
among the 107 miRNA validated from the discovery set of 179 miRNAs. Comparing ﬁve
MG patients with MuSK antibodies (MuSK+) versus ﬁve healthy controls, miRNAs were
selected when a p-value b0.05 was found on unpaired two-sided t-test and the miRNAs
were elevated in each individual MuSK+ MG patient compared to its matched healthy
control (bold).
microRNA Fold change (log)
elevated
Fold change (log)
reduced
p-Value
hsa-miR-151a-3p 2.63 0.000887
hsa-let-7f-5p 3.76 0.01040
hsa-miR-423-5p 4.30 0.0118
hsa-let-7d-3p 3.68 0.0178
hsa-miR-10b-5p 3.48 0.0247
hsa-miR-376c-3p 3.75 0.0324
hsa-let-7a-5p 2.03 0.0327
hsa-miR-484 3.17 0.0342
hsa-miR-409-3p 4.46 0.0351
hsa-miR-421 2.99 0.0447
hsa-miR-25-3p 1.95 n.s.
hsa-miR-140-3p 1.05 n.s.
Fig. 1. Volcano plot of the 107 expressed miRNAs in the discovery set (N = 10). The
differentially expressed miRNAs with p ≤ 0.05 on t-test (yellow dots; shown in Table 2)
were further analyzed in the validation set. All dots under the red line (gray or red) did
not differentiate between MuSK+ MG patients (MG; N = 5) and healthy controls (Ctrl;
N = 5). The Y-axis represents 10 log of the p-value and the X-axis represents log fold
change of miRNA expression in the MG versus healthy controls.
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gested candidate genes using the “NormFinder and geNorm” applica-
tions available in the GenEx software, we chose reference miRNAs
miR-191-5p and miR-103a-3p.
2.3.2. Screening of the individual miRNAs
The qRT-PCR analysis was performed using ExiLENT SYBR® Green
master mix (Exiqon #203420) on custom made 384-well Pick-&-Mix
microRNA PCR panel plates (Exiqon #203815) pre-coated with validat-
ed primer sets to amplify targetmiRNAs. The cDNAreactionswere dilut-
ed 100× in ExiLENT SYBR® Green master mix before being applied to
the Pick-&-Mix microRNA PCR panel plates. All qRT-PCR reactions
were analyzed with the Applied Biosystems 7900HT Fast Real-Time
PCR System (Life Technologies) as described previously (Punga et al.,
2014). The following quality controls were included on Pick-&-Mix
microRNA PCR panel plates: inter-plate calibration (UniSp3), RNA
extraction control (UniSp2 and UniSp4), cDNA synthesis control
(UniSp6) and hemolysis test (miR-23a-3p–miR-451a) (all from
Exiqon). The ΔCT value of hemolysis markers (ΔCT(hemolysis) =
CT(miR-23a-3p) − CT(miR-451a)), was used to detect hemolysis. A
ΔCT N 7 in serum samples indicates a high risk of hemolysis and
therefore these samples were not used for further analysis.
Normalization of individual miRNA levels was done according to
GenExmanual guidelines (Exiqon). Relative quantities for the discovery
cohort were calculated by using the healthy blood donors as a control
group. Quantiﬁcation of relative miRNA expression on the validation
set was performed with the comparative CT method using the formula
2−ΔΔCT, where ΔCT = (CT gene of interest − CT reference gene) of
each sample, using miR-191-5p and miR-103a-3p as the reference
miRNA (Schmittgen and Livak, 2008).
2.4. Statistical analysis
Log conversion of the data in the discovery set was done in order to
obtain datamore similar to a normal distribution for the statistical tests.
An unpaired two-tailed t-test of independent samples was performed,
comparing MG and control groups with the null hypothesis that the
mean values of the differentmiRNAswere the same acrossMG and con-
trol categories. In the discovery set, candidate miRNAs were selected if
they were signiﬁcantly differentially expressed in the MG versus HC
group. Exclusively miRNAs that were found to be reduced or elevated
in each individual patient compared to his/her matched control were
selected for the validation set analysis. Spearman Rank correlation was
performed in order to determine the correlation coefﬁcient between
disease duration, MuSK ab titer, age and differentially expressed
miRNAs. Statistical signiﬁcance was deﬁned as p b 0.05.
3. Results
3.1. Circulating miRNA proﬁle in MuSK+MG patient sera in the discovery
set (N = 10)
The discovery set included ﬁve MuSK+ MG patients (mean age:
49 ± 10 years; 4 women) who had mean disease duration of 20 ± 15
years. In this cohort, age of MG onset ranged from 13 to 52 years of
age. Three patients were currently on immunosuppressive treatment
and two patients (#1 and #5) had undergone thymectomy (Table 1).
These patients were age- and gender-matched with ﬁve healthy blood
donors (mean age: 48 ± 10 years, 4 women) without any diagnosed
disease. Patients #1,2,3 and 4 had no concomitant disease, whereas pa-
tient #5 had thyroiditis.
The ﬁrst stepwas to evaluate the circulatingmiRNA proﬁle in sera of
patients with MuSK+ MG. For this purpose, the discovery set samples
of ﬁve MuSK+ MG patients and ﬁve age- and gender-matched HCs
were analyzed. Importantly, none of the discovery set serum samples
showed signiﬁcant signs of hemolysis (ΔCT b 6.5). Normalization ofthe miRNA expression was done using the recommended reference
miRNAs (miR-191-5p and miR-103a-3p). Out of 179 tested miRNAs,
107 miRNAs showed ampliﬁcation in more than 60% of the samples
and were thus further analyzed. Twelve miRNAs were found to be
strongly elevated or reduced in the MuSK+ MG patients (Table 2).
Out of these candidates, 10 miRNAs had p-values b0.05 after statistical
analysis with t-test, visualized in the volcano plot (Fig. 1). These data
were supported by principal component analysis (Supplemental
Fig. 1), indicating different expression of the 10 miRNAs between MG
patients and HC. Clustering of different miRNAs in a heat map analysis
was in accordance with these data (Supplemental Fig. 2).
3.2. Individual validation of the miRNA expression pattern (N = 40)
The six miRNAs that were found to be signiﬁcantly altered between
all individual MuSK+ MG patients and HCs in the discovery set
(Table 1) were further analyzed by qRT-PCR in sera from a larger Italian
cohort. The validation cohort included 20 MuSK+ MG patients (mean
age: 44 ± 16 years; 13 women) who had mean disease duration of
7 ± 6 years. Age at disease onset in this MuSK+ MG cohort ranged
from 13 to 71 years of age. SixteenMuSK+MG patients were immuno-
suppressed at the time of sampling and one had undergone
24 T. Punga et al. / Journal of Neuroimmunology 292 (2016) 21–26thymectomy. Concomitant diseases were observed in ﬁve patients. Pa-
tient #11 had polycythemia, #21 had cerebral stroke, #26 and #30
had thyroiditis and #27 had cardiomyopathy. The patients were age-
and gendermatchedwith 20HC (mean age: 44±16 years; 13women).
The haemolysis quote (ΔCT(haemolysis) = CT(miR-23a-3p) − CT(miR-
451a)) was b6 in all MG and HC sera; hence all samples were further
processed. All selected miRNAs of interest had a stable ampliﬁcation
in all of the individual samples with good expression (CT ≤ 34), ex-
cept for one MuSK+ MG sample (M17; Table 1) and one healthy
control (C41; Table 1), with reference CT N 35, and were thus ex-
cluded. Based on these results, we were able to validate four
miRNAs that were differentially expressed in MuSK+ MG patients
and HCs: miR-151a-3p (p = 0.0212; Fig. 2A), let-7a-5p (p =
0.0464; Fig. 2B), let-7f-5p (p = 0.0050; Fig. 2C) and miR-423-5pFig. 2. Signiﬁcantly alteredmiRNAs inMG patients (N= 19) compared to age- and gender-mat
median ± interquartile range (bars) are shown for the assayed miRNAs in the validation coho
miR409-3p (F). *p ≤ 0.05; **p ≤ 0.01.(p = 0.0473; Fig. 2D), whereas let-7d-3p (p = 0.115; Fig. 2E) and
miR-409-3p (p = 0.8234; Fig. 2F) were not signiﬁcantly altered in
the validation cohort. The ROC curve (area under the curve; AUC)
for these validated, deregulated miRNAs displayed the strongest as-
sociation with MG for miR-151a-3p and miR-423-5p (both AUC of
0.740), followed by let-7f-5p (AUC of 0.726) and let-7a-5p (AUC
of 0.659) (Fig. 3). Disease duration among the validation cohort of
MuSK+ MG patients ranged from 1 to 18 years (mean 6.9 ±
6.0 years). We found no correlation between disease duration and
expression level of any miRNA (p N 0.05). There was a correlation
between MuSK ab titer and clinical score (R = 0.67; p = 0.002),
however there was no signiﬁcant correlation between individual
miRNAs and MuSK ab titres or between miRNA levels and disease
severity (data not shown).ched healthy blood donors (N= 19). Relative expression with individual values as well as
rt: hsa-miR-151a-3p (A), let-7a-5p (B), let-7f-5p (C), miR-423-5p (D), let-7d-3p (E) and
Fig. 3. ROC curve of all altered miRNAs, indicating sensitivity of each miRNA for MG: miR-151a-3p (A), let-7a-5p (B), let-7f-5p (C) and miR-423-5p (D).
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In the present report we have analyzed the presence and abundance
of circulating miRNAs in MuSK+ MG patient sera. Out of 179 analyzed
miRNAs, four miRNAs: let-7a-5p, let-7f-5p, miR-151a-3p and miR-423-
5p, showed signiﬁcant enrichment inMuSK+MGpatient sera. Previous
reports observed elevated levels of circulatingmiR-150-5p andmiR-21-
5p in the sera of AChR+MGpatients, with lower levels in immunosup-
pressed patients (Punga et al., 2015). Additionally, miR-150-5p was re-
duced upon thymectomy in correlation with clinical improvement
(Punga et al., 2014). In contrast to AChR+ MG, thymus pathology is
very uncommon in MuSK+ MG, where the thymus does not seem to
play a pathogenic role (Marx et al., 2013). We chose not to include
AChR+ patients in this study as a third comparator, since the previous
study on circulating miRNA proﬁle in AChR+ MG did not indicate any
changed proﬁle of any of the miRNAs let-7a-5p, let-7f-5p, miR-151a-
3p or miR-423-5p (Punga et al., 2014). Together with the difference be-
tween IgG1 AChR abs and IgG4 MuSK abs, it is not unexpected that
AChR+ MG and MuSK+ MG are associated with different circulating
serummiRNAs.
Themembers of the let-7miRNA family are among themost studied
miRNAs since they possess a functional impact on various cellular pro-
cesses including embryogenesis, neuronal development and glucose
metabolism (Gurtan et al., 2013; Patterson et al., 2014; Zhu et al.,
2011). Twelve different let-7 family members (let-7a-1, let-7a-2, let-
7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-1, let-7f-2, let-7 g, let-7i, and
miR-98) are expressed in human cells (Roush and Slack, 2008). In addi-
tion to their intracellular roles, several members of the let-7 miRNA
family have been shown to be incorporated into exosomes and actively
secreted into the extracellular environment in the gastric cancer cell lineAZ-P7a (Ohshima et al., 2010). Quantiﬁcation of the circulatingmiRNAs
in ovarian cancer and in non-small-cell lung carcinoma patient sera has
shown that let-7b and let-7f are signiﬁcantly underrepresented in these
patient sera (Chung et al., 2013; Silva et al., 2011). In contrast, the pres-
ent study identiﬁed selective enrichment of two let-7 miRNA family
members, let-7a-5p and let-7f-5p, in MuSK+ MG sera. In accordance
with our data, members of the let-7 miRNA family are highly elevated
in the sera of patients withmultiple sclerosis (MS) compared to healthy
individuals (Gandhi et al., 2013). Especially, circulating serum let-7a
shows signiﬁcant enrichment in patients with secondary progressive
MS (Gandhi et al., 2013). Thus, the enrichment of circulating serum
let-7 miRNAs might be a selective feature that patients with MuSK+
MG and MS have in common.
One function of the let-7 miRNAs in the immune response is T cell
activation through stimulation of the toll-like receptor 7 (TLR7)
(Wang et al., 2011). Intriguingly, engagement of TLR7 in CD4+T cells ac-
tually induces unresponsiveness of T cells (Dominguez-Villar et al.,
2015). One confounding factor in our cohort was the large number of
immunosuppressed patients, since immunosuppression is known to at-
tenuate the Th1 response in MuSK+ MG (Yilmaz et al., 2015). This
problem is difﬁcult to counteract, considering the relatively small inter-
national cohort of MuSK+MG patients. On the contrary, lower levels of
let-7miRNAswere previously reported in peripheral bloodmononucle-
ar cells from MG patients compared to healthy controls (Jiang et al.,
2012). Nevertheless, in this particular study the authors did not present
antibody status of the MG patients, thus not allowing any comparison
with our data. A previous Spanish study examined circulating miRNA
of MG patients, however in this study only AChR+ patients were in-
cluded and thus we cannot make direct comparisons to circulating
miRNA proﬁles of our MuSK+ patients (Nogales-Gadea et al., 2014).
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were miR-151a–3p and miR-423-5p. Unlike the established immune-
miRNA, miR-150-5p (Kroesen et al., 2015), miR-151-3p is instead
known as an oncomir (Chiyomaru et al., 2012). Increased levels of circu-
lating miR-151–3p are considered a positive indicator, and thus useful
biomarker in clinical trials for breast cancer (Krell et al., 2012). In addi-
tion, circulating miR-151-3p levels have been found to be reduced im-
mediately following aerobic exercise (Nielsen et al., 2014).
The last elevated miRNA, miR-423-5p, has been conﬁrmed to be el-
evated in plasma from patients with heart failure and to be predictive
of its severity (Tijsen et al., 2010). Nevertheless, none of the patients
in our study had any signs of heart failure. Regarding concomitant dis-
eases, three patients had thyroiditis and three others had cardiomyopa-
thy, cerebral stroke and polycythemia respectively. This low prevalence
of concomitant diseases does not make us suspect that the observed
miRNA proﬁle was due to another disease process than MuSK+ MG.
Themain limitation of the present study is that the group ofMuSK+pa-
tients consists of a cross-sectional sample with relatively long disease
duration aswell as immunosuppressive treatment in themajority of pa-
tients. Although we did not ﬁnd any particular correlation between dis-
ease duration and any of the expressed miRNAs, both long disease
duration and concomitant medication could serve as potential con-
founders that may impact on outcome. Further, although all patients
had a normal thymus as is commonly seen in MuSK+ MG (Marx
et al., 2013), we cannot exclude that thymectomy impacted the
miRNA proﬁle in a few patients.
In summary, the present study deﬁned four circulating miRNAs
that were elevated in MuSK+ MG subtype. The identiﬁed miRNAs:
let-7a-5p, let-7f-5p, miR-151a-3p and miR-423-5p, all could serve
as potential biomarkers in addition to ab titres inMuSK+MG. There-
fore, we suggest further validation of these biomarkers in a larger in-
ternational cohort with a longitudinal follow-up study for diagnostic
and therapeutic purposes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jneuroim.2016.01.003.
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